Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients
Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients - an Observational Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Zuid-holland
-
Leiden, Zuid-holland, Netherlands, 2333ZA
- Leiden University Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria Covid-19 group:
- Covid-19 disease proven by PCR of nose- or airway sample
- Age ≥ 18 years
- Admitted to the ICU from the 15th of March 2020 until 1st of January 2022
- Treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml
Inclusion Criteria non-Covid-19 group:
- Age ≥ 18 years
- Admitted to the ICU between the 1st of January 2014 and 1st of January 2020
- Treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml
Exclusion Criteria:
- Treatment with anticoagulants other than UFH or fibrinolytics
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Covid-19 patients
Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml.
All patients have Covid-19 proven by PCR or nose- or airway swab.
Patients admitted to the ICU from the 15th of March 2020 until January 2022.
|
Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
|
|
non-COVID-19 patients
Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml.
Patients admitted to the ICU between the 1st of January 2014 and the 1st of January 2020 are included.
|
Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heparin dosage
Time Frame: Until end of heparin therapy or ICU discharge, whatever comes first.
|
To determine whether heparin dosages are higher in COVID-19 patients compared to non COVID-19 patients.
|
Until end of heparin therapy or ICU discharge, whatever comes first.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between aPTT and anti-Xa values
Time Frame: Until end of heparin therapy or ICU discharge, whatever comes first.
|
To explore possible causes for non-correlating aPTT and Anti-Xa levels
|
Until end of heparin therapy or ICU discharge, whatever comes first.
|
|
Correlation between non-correlating aPTT and Anti-Xa levels and CRP
Time Frame: Until end of heparin therapy or ICU discharge, whatever comes first.
|
To explore possible causes for non-correlating aPTT and Anti-Xa levels
|
Until end of heparin therapy or ICU discharge, whatever comes first.
|
|
Correlation between non-correlating aPTT and Anti-Xa levels and AT plasma levels
Time Frame: Until end of heparin therapy or ICU discharge, whatever comes first.
|
To explore possible causes for non-correlating aPTT and Anti-Xa levels
|
Until end of heparin therapy or ICU discharge, whatever comes first.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Evert de Jonge, MD, PhD, Leiden University Medical Centre
Publications and helpful links
General Publications
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum In: Lancet Respir Med. 2020 Apr;8(4):e26.
- Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T, Cattaneo M. Type and dose of heparin in Covid-19: Reply. J Thromb Haemost. 2020 Aug;18(8):2063-2064. doi: 10.1111/jth.14870. Epub 2020 May 11. No abstract available.
- Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin? Thromb Res. 2017 Sep;157:157-161. doi: 10.1016/j.thromres.2017.07.006. Epub 2017 Jul 6.
- White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, Lavinio A, Varley J, Johnston A, Besser M, Thomas W. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0. Erratum In: J Thromb Thrombolysis. 2020 Jun 22;:
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Heparin
- Calcium heparin
Other Study ID Numbers
Other Study ID Numbers
- CoCo 2022-020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.